The adverse reaction profile was similar across these studies In clinical trials of modafinil, the incidence of rash resulting in discontinuation was approximately 0.8% (13 per 1,585) in pediatric patients (age <17 years); these rashes included 1 case of possible Stevens-Johnson Syndrome (SJS) and 1 case of apparent multi-organ. This smart drug trial pack is a convenient alternative which offers you two different nootropic medicines to suit your needs This pilot study is an eight-week, randomized, double-blind, placebo-controlled, escalating dose trial of the novel vigilance-promoting drug, modafinil, added to a stable dose of clozapine in 40 patients with schizophrenia or schizoaffective disorder. It is taken by mouth Modafinil has been evaluated for safety in over 3500 patients, of whom more than 2000 patients with excessive sleepiness associated with primary disorders of sleep and wakefulness were given at least one dose of modafinil. And the more pills their research subjects took at once, the more likely they were to report side effects Modafinil, sold under the brand name Provigil among others, is a medication to treat sleepiness due to narcolepsy, shift provigil trial work sleep disorder, or obstructive sleep apnea. Objective: To assess the efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis (MS). While it has seen off-label use as a purported cognitive enhancer, the research on its effectiveness for this use is not conclusive We investigated the efficacy of the noradrenergic and serotonergic antidepressant mirtazapine (15–60 mg per day, n=13), and the wake-promoting drug, modafinil (400mg per day, n=14) in successive, open-label pilot trials in inpatients undergoing withdrawal management The overall trial end date was changed from 09/01/2020 to 16/02/2021. In placebo-controlled clinical trials, the most common adverse reactions ( ≥ 5%) associated with the use of PROVIGIL more frequently than placebo-treated patients were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness, and dyspepsia. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Cognitive enhancing effects of modafinil in healthy volunteers Modafinil also significantly improved sleep latency and CGI-C scores in 2 clinical trials of patients with obstructive sleep apnea/hypopnea. US Modafinil in Narcolepsy Multicenter Study Group. Provigil in clinical trials. 8,9 Approximately 80% of patients in these studies were using their continuous positive airway pressure devices. The overall trial end date has been changed from 21/10/2018 to 09/01/2020 2 MODAFINIL is used to treat excessive sleepiness caused by certain sleep disorders. Seventy-two people with different forms of MS took two different doses of modafinil. Modafinil is used to help people who have narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS), or shift work sleep disorder (SWSD) to stay awake during the day CLINICAL TRIALS. The overall trial end date was changed from 09/01/2020 to 16/02/2021. Despite never attaining FDA approval for the treatment of depression, many anecdotal reports highlight the efficacy of Provigil as an antidepressant. It doesn’t make you speedy or jittery like most classical stimulants do. If all else fails, there's Ritalin or Adderall, if my heart rate doesn't hit the roof Modafinil has been tested in clinical trials to alleviate fatigue in multiple sclerosis and inpatient stroke patients with mixed results in small or incomplete studies. 13,14 The aim of this trial was to assess the effects of modafinil in strokes survivors, 3 or more months after their event with significant fatigue as measured by the. 2009; 62:243–249. you can find the drug in the United States, in a brand name Provigil.Also, with the help of the drug, you will be able to cope up with various sleep. In clinical trials, modafinil has been found to be generally well tolerated and most adverse experiences were mild to moderate Objectives: To assess the long-term efficacy and safety of modafinil in patients with excessive daytime sleepiness (EDS) associated with narcolepsy Background: Modafinil has been shown to be effective and well tolerated for treating EDS associated with narcolepsy in two large-scale, well-controlled, 9-week clinical trials Methods: Four hundred and seventy eight adult patients with a. Methods: Patients aged 18–65 years with a diagnosis of MS, a stable disability level ≤6 on the Kurtzke extended disability status scale (EDSS), and a mean score >4 on the fatigue severity scale (FSS) were eligible for the 9 week, single blind, phase 2, two centre study.